Medtronic (NYSE:MDT) Research Coverage Started at Citigroup

Citigroup started coverage on shares of Medtronic (NYSE:MDT) in a report issued on Tuesday morning, Marketbeat.com reports. The firm issued a buy rating and a $117.00 price objective on the medical technology company’s stock.

Other equities research analysts have also issued research reports about the company. JPMorgan Chase & Co. boosted their price target on Medtronic from $90.00 to $100.00 and gave the stock a “neutral” rating in a research note on Thursday, November 13th. Morgan Stanley boosted their target price on shares of Medtronic from $107.00 to $117.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 19th. Barclays raised their price target on shares of Medtronic from $111.00 to $116.00 and gave the stock an “overweight” rating in a report on Thursday, January 8th. Piper Sandler reissued a “neutral” rating on shares of Medtronic in a report on Monday, January 5th. Finally, Leerink Partners set a $120.00 target price on Medtronic and gave the stock an “outperform” rating in a research note on Wednesday, November 19th. Fifteen analysts have rated the stock with a Buy rating and eleven have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $110.67.

Medtronic Price Performance

Shares of MDT opened at $102.92 on Tuesday. The company has a 50 day moving average of $99.44 and a two-hundred day moving average of $96.01. The company has a quick ratio of 1.80, a current ratio of 2.42 and a debt-to-equity ratio of 0.57. Medtronic has a twelve month low of $79.55 and a twelve month high of $106.33. The company has a market cap of $131.95 billion, a price-to-earnings ratio of 27.74, a price-to-earnings-growth ratio of 2.68 and a beta of 0.71.

Medtronic (NYSE:MDT) last issued its quarterly earnings results on Tuesday, November 18th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.31 by $0.05. The business had revenue of $8.96 billion for the quarter, compared to the consensus estimate of $8.86 billion. Medtronic had a return on equity of 14.86% and a net margin of 13.71%.The business’s quarterly revenue was up 6.6% on a year-over-year basis. During the same period in the prior year, the firm posted $1.26 earnings per share. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. As a group, analysts predict that Medtronic will post 5.46 earnings per share for the current fiscal year.

Medtronic Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, January 16th. Shareholders of record on Friday, December 26th were paid a dividend of $0.71 per share. The ex-dividend date was Friday, December 26th. This represents a $2.84 dividend on an annualized basis and a dividend yield of 2.8%. Medtronic’s dividend payout ratio (DPR) is presently 76.55%.

Institutional Trading of Medtronic

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. AXQ Capital LP grew its stake in shares of Medtronic by 25.6% during the 2nd quarter. AXQ Capital LP now owns 9,890 shares of the medical technology company’s stock worth $862,000 after purchasing an additional 2,013 shares during the period. UMB Bank n.a. lifted its stake in shares of Medtronic by 65.8% in the third quarter. UMB Bank n.a. now owns 138,278 shares of the medical technology company’s stock valued at $13,170,000 after purchasing an additional 54,898 shares during the period. Principal Financial Group Inc. boosted its holdings in Medtronic by 17.2% during the third quarter. Principal Financial Group Inc. now owns 1,656,155 shares of the medical technology company’s stock worth $157,732,000 after buying an additional 242,910 shares in the last quarter. Sector Gamma AS grew its position in Medtronic by 35.5% during the third quarter. Sector Gamma AS now owns 303,441 shares of the medical technology company’s stock worth $28,900,000 after buying an additional 79,441 shares during the period. Finally, Merit Financial Group LLC increased its holdings in Medtronic by 37.5% in the second quarter. Merit Financial Group LLC now owns 57,035 shares of the medical technology company’s stock valued at $4,972,000 after buying an additional 15,561 shares in the last quarter. 82.06% of the stock is owned by institutional investors and hedge funds.

Key Medtronic News

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Analysts remain constructive — several outlets highlight bullish analyst views on Medtronic, supporting confidence in longer‑term growth prospects. Analysts Are Bullish on These Healthcare Stocks: Medtronic (MDT)
• Positive Sentiment: Product/market expansion — coverage notes Medtronic is broadening its heart and diabetes tools and integrating new offerings, which can support revenue growth and investors’ valuation assumptions. Medtronic Expands Heart And Diabetes Tools As Valuation Nears Analyst Views
• Positive Sentiment: Strategic M&A — Medtronic expanded its cath lab portfolio with the CathWorks acquisition, strengthening structural/cath lab offerings and cross‑sell opportunities. That helps offset competitive pressure in some device categories. Medtronic expands cath lab portfolio with CathWorks acquisition
• Neutral Sentiment: New analyst coverage — Citigroup began coverage of MDT, which can increase analyst attention and trading liquidity; the ultimate impact depends on the published rating and target. Citigroup Begins Coverage on Medtronic (NYSE:MDT)
• Neutral Sentiment: Valuation and investor commentary are mixed — several pieces debate whether recent gains leave MDT reasonably priced; these discussions can moderate momentum but don’t directly change fundamentals. Is Medtronic (MDT) Still Reasonably Priced After Recent Share Price Gains?
• Neutral Sentiment: Leadership change — the president of Structural Heart, Nina Goodheart, is retiring; this is notable for execution risk in that business but not an immediate financial shock. Medtronic Structural Heart President Nina Goodheart to retire
• Neutral Sentiment: Market performance context — one note shows MDT outperformed intraday but underperformed peers on the day, signaling relative-strength questions even amid gains. Medtronic PLC stock underperforms Thursday when compared to competitors despite daily gains
• Negative Sentiment: Major legal setback — a U.S. jury found Medtronic unlawfully monopolized the market for certain vessel‑sealing devices and ordered roughly $382 million in damages to Applied Medical; this is the most immediate negative catalyst and creates financial, reputational and potentially precedent risks. Medtronic owes $382 million to medical device rival in antitrust lawsuit, US jury says Applied Medical Prevails in Antitrust Jury Trial Against Medtronic

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).